Immunodeficiency News and Research

RSS

Immunodeficiency (or immune deficiency) is a state in which the immune system's ability to fight infectious disease is compromised or entirely absent.

Study reveals the role of intracellular receptor PQBP1 in response to Tau protein

Just as a home security system can alert a homeowner to the presence of an intruder, a protein called polyglutamine binding protein-1 (PQBP1) found in brain cells can alert the body to the presence of "intruding" viruses like human immunodeficiency virus (HIV).

9 Dec 2021

Increased risk of COVID-19 breakthrough infections in fully vaccinated people with HIV

New study results showed a 41% greater incidence of breakthrough infections in people with HIV compared to that of people without HIV.

9 Dec 2021

Breastmilk T cell repertoire is enriched for SARS-CoV-2 Spike-specificity after maternal mRNA vaccination

New study demonstrates that it is possible one day that breastmilk samples will be used to characterize broad mucosal immunity after vaccination.

8 Dec 2021

Octapharma USA announces FDA approval of cutaquig 16.5% for pediatric PI patients

Octapharma USA today announced the U.S. Food & Drug Administration has approved cutaquig [Immune globulin, Subcutaneous (Human)-hipp, 16.5% Solution] for the treatment of pediatric patients age 2 and older with primary humoral immunodeficiency (PI). The FDA previously approved cutaquig for adults with PI.

7 Dec 2021

In-depth analysis of SARS-CoV-2 specific T cells in unexposed individuals

A new study aimed to analyze SARS-CoV-2 specific T-cells in unexposed individuals.

2 Dec 2021

Impact of SARS-CoV-2 on oral health

New research examined SARS-CoV-2 and its impact on oral health and suggests that survival against the infection may be partially dependent on such factors.

1 Dec 2021

WHO recommends the use of first long-acting option to protect women from HIV

The first long-acting option to protect women from HIV, proven to reduce women's HIV risk, has been recommended for use by the World Health Organization.

1 Dec 2021

Study finds atazanavir inhibits main SARS-CoV-2 protease

Research shows that ATV has different antiviral activity compared to PAXLOVID™, encouraging further research.

29 Nov 2021

Time of starting antiretroviral therapy can influence tumor development In HIV patients

HIV patients have an increased risk of developing skin and mucosal cancers, even though HIV is no longer detectable in their blood due to antiretroviral therapy.

23 Nov 2021

IFITM proteins are important replication cofactors for SARS-CoV-2, including Delta variant

In a study recently published on the bioRxiv* preprint server, researchers investigated the IFITM2 dependency of SARS-CoV-2 VOCs, including the delta variant for efficient infection.

22 Nov 2021

Characterization of B-cell receptor repertoires in COVID-19 patients

In a new study published in the journal Human Immunology, scientists sought to better understand how B-cell immune repertoire changes over time during SARS-CoV-2 infection by comprehensively characterizing the dynamics of immunoglobin heavy chain (IGH) repertoire in COVID-19 patients.

22 Nov 2021

Study finds no increased risk of severe COVID-19 in immunocompromised children in UK

Researchers conducted a prospective study to describe the incidence and clinical spectrum of SARS-CoV-2 infection in a UK-wide cohort of immunocompromised children.

22 Nov 2021

Novel technique solves structure of the HIV capsid alone and in complex with host factors

A new technique using electron tomography and subtomogram averaging at Diamond's electron Bio-Imaging Centre (eBIC), has solved the structure of the HIV capsid alone and in complex with host factors.

21 Nov 2021

First long-acting injectable HIV treatment appraised and approved by NICE

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc, with Pfizer Inc. and Shionogi Limited as shareholders, is pleased to announce that eligible people living with Human Immunodeficiency Virus (HIV) in England and Wales will soon have routine access to Vocabria (cabotegravir long-acting injection) developed by ViiV Healthcare in combination with Rekambys (rilpivirine long-acting injection), developed by Janssen Sciences Ireland UC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

19 Nov 2021

Immunodeficiency News and Research

Further Reading

Study reveals the role of intracellular receptor PQBP1 in response to Tau protein

Increased risk of COVID-19 breakthrough infections in fully vaccinated people with HIV

Breastmilk T cell repertoire is enriched for SARS-CoV-2 Spike-specificity after maternal mRNA vaccination

Octapharma USA announces FDA approval of cutaquig 16.5% for pediatric PI patients

In-depth analysis of SARS-CoV-2 specific T cells in unexposed individuals

Impact of SARS-CoV-2 on oral health

WHO recommends the use of first long-acting option to protect women from HIV

Study finds atazanavir inhibits main SARS-CoV-2 protease

Time of starting antiretroviral therapy can influence tumor development In HIV patients

IFITM proteins are important replication cofactors for SARS-CoV-2, including Delta variant

Characterization of B-cell receptor repertoires in COVID-19 patients

Study finds no increased risk of severe COVID-19 in immunocompromised children in UK

Novel technique solves structure of the HIV capsid alone and in complex with host factors

First long-acting injectable HIV treatment appraised and approved by NICE

Viral biomolecular condensation

Analysis of immunodeficient patients granted REGEN-COV under compassionate use COVID-19 program

Hemin as a potential therapy for COVID-19

Oral SARS-CoV-2 Mpro inhibitor for therapeutic use

Trends in SARS-CoV-2 seroprevalence in Massachusetts

Curcumin, a bioactive component of turmeric, effectively neutralizes SARS-CoV-2 in vitro

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News